Alisa B. Busch

Alisa B. Busch

Auto-generated profile, based on publicly available information

Alisa B. Busch

McLean Hospital, Belmont, Massachusetts

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 January 2021 in Neuropsychopharmacology
Verified
Journal Article
Closed access
PDF file
ABAlisa B. Busch
Alisa B. Busch
DSDawn E. Sugarman
Dawn E. Sugarman
LHLisa E. Horvitz
Lisa E. Horvitz
SGShelly F. Greenfield
Shelly F. Greenfield

28 January 2022 in JAMA Network Open
Verified
Journal Article
Open access
PDF file
ABAlisa B. Busch
Alisa B. Busch
HHHaiden A. Huskamp
Haiden A. Huskamp
PRPushpa Raja
Pushpa Raja
SRSherri Rose
Sherri Rose
AMAteev Mehrotra
Ateev Mehrotra
Individuals with a severe mental illness, such schizophrenia or bipolar I disorder, may be particularly vulnerable to care disruptions during the ongoing COVID-19 pandemic. They frequently are marginalized, have disability, are unhoused, live in poverty, and are more socially isolated.1,2 While telemedicine use increased in the pandemic and is feasible in treating psychotic disorders,3,4 some individuals with severe mental illness lack the tools or digital literacy to use telemedicine.5-7 Additionally, they have higher rates of chronic medical conditions that are associated with greater risk of COVID-19 morbidity and mortality8-10—such as diabetes, cardiovascular disease, hypertension, and chronic lung disorders11,12—and therefore may be more reluctant to seek in-person care. Together, these factors may cause some to forgo needed outpatient care which in turn could result in greater use of emergency care.13-15 Additionally, the pandemic may exacerbate preexisting disparities among individuals who belong to racial or ethnic minority groups or rural residents.16-23

1 May 2004 in Archives of General Psychiatry
Verified
Journal Article
Open access
PDF file
ABAlisa B. Busch
Alisa B. Busch
RFRichard G. Frank
Richard G. Frank
ALAnthony F. Lehman
Anthony F. Lehman
Managed behavioral health carve-outs (MBHCOs) are a regular featureof the mental health care delivery landscape1 andhave been successful in reducing costs.2-4 Asstates struggle to control Medicaid spending, they have turned to managedbehavioral health care organizations to ration public mental health–substanceabuse (MH/SA) care. More than 20 states have adopted carve-outs to manageMH/SA care in the Medicaid program.1 Carve-outsserve to separate part of the risk in a health insurance arrangement and manageit under a separate contract. Two sets of health insurance risks where thisoccurs frequently are mental health and substance abuse care (together referredto as behavioral health care) and prescription medications.There are several different approaches to organizing carve-out arrangements.5

28 August 2021 in Drug and Alcohol Dependence
Verified
Journal Article
Closed access
LRLauren Riedel
Lauren Riedel
LULori Uscher-Pines
Lori Uscher-Pines
AMAteev Mehrotra
Ateev Mehrotra
ABAlisa B. Busch
Alisa B. Busch
MBMichael L. Barnett
Michael L. Barnett
HHHaiden A. Huskamp
Haiden A. Huskamp

1 February 2009 in Medical Care
Verified
Journal Article
Closed access
ABAlisa B. Busch
Alisa B. Busch
ALAnthony F. Lehman
Anthony F. Lehman
HGHoward Goldman
Howard Goldman
RFRichard G. Frank
Richard G. Frank
Schizophrenia medication and psychosocial treatment options have expanded since the Schizophrenia PORT was conducted. However, there also have been considerable changes in the delivery of mental health care in the public sector, as well as increasing state concerns about Medicaid cost containment. To examine trends and patient characteristics associated with differences in schizophrenia medication and visit treatment quality in a Medicaid population. Observational study of claims data from July 1, 1996 to June 30, 2001. Florida Medicaid enrollees diagnosed with schizophrenia (N = 23,619). We examined the likelihood of meeting any 1 and all 4 of the following quality standards: (1) receiving antipsychotic medication, (2) antipsychotic continuity, (3) dosing consistent with PORT recommendations, and (4) mental health visit continuity. Separate models were fit for acute and maintenance phases of treatment. Approximately 18% of acute and 7% of maintenance phases met all 4 quality standards. Antipsychotic quality improved (largely driven by an increasingly likelihood of receiving any antipsychotic), while visit continuity declined. The greatest disparities were seen for persons with co-occurring substance use disorders and of black race. Quality differences were often phase specific and at times in opposite directions across treatment phases. The improvement in antipsychotic treatment quality is encouraging. However, visit continuity declined. This study highlights the importance of quality measurement that includes focus on different treatment modalities and phases of care, as well as for potentially vulnerable populations (such as persons with co-occurring substance use disorders and racial/ethnic minorities).

1 February 2013 in American Journal of Psychiatry
Verified
Journal Article
Closed access
ABAlisa B. Busch
Alisa B. Busch
FYFrank Yoon
Frank Yoon
CBColleen L. Barry
Colleen L. Barry
VAVanessa Azzone
Vanessa Azzone
SNSharon-Lise T. Normand
Sharon-Lise T. Normand
DMDennis McCarty
Dennis McCarty